Bipartisan Senate Finance Framework Takes ‘Measured’ Aim At PBMs
Executive Summary
Framework from Sens. Wyden and Crapo, looks like it would change, but not eliminate, the rebate system and gets an initial thumbs up from both the brand and generic drug lobbies.
You may also be interested in...
PBM Rebates Drive List-To-Net Price Gap For Insulins, Study Shows; More Fodder For Reforms?
Mandatory government discounts had a much smaller impact on net prices than voluntary rebates in commercial and Medicare Part D plans, researchers determine. The cap on Medicaid rebates, which will be eliminated in 2024, may have contributed to at least some of the disparity.
PBM Compensation 'Delinked' From List Price, Utilization In Medicare Part D Under Senate Bill
Legislation focuses on key aspect of Senate Finance Committee framework for reforming pharmacy benefit managers, reflecting concerns that current compensation practices reward PBMs for higher list prices and increase costs for patients. It does not take direct aim at rebates.
Senate Committee Passes Moderate PBM Reform, But Has Its Eyes On Stronger Policies
Delinking pharmacy benefits managers’ compensation from the prices of drugs received bipartisan rhetorical support at a HELP markup, but the panel only cleared less drastic PBM reforms along with generic and orphan-drug focused policies. Approved amendments tackled step therapy, pharma transparency and PBM gag clauses, among other topics.